{
  "nodes": [
    {
      "id": "N1",
      "label": "Step 1",
      "customData": {
        "node_id": "A",
        "node_step_index": 0,
        "content": "October 2020: 81-year-old man diagnosed with lung adenocarcinoma (T4N2M1).",
        "clinical_data": {
          "diagnoses": [
            {
              "code": "C0242398",
              "label": "Adenocarcinoma of lung",
              "status": "active",
              "onset_date": "2020-10"
            }
          ]
        }
      },
      "custom_id": "graph_072_N0"
    },
    {
      "id": "N2",
      "label": "Step 2",
      "customData": {
        "node_id": "B",
        "node_step_index": 1,
        "content": "November 2020: Received gyroknife radiotherapy for left and right lung malignancies 12 times.",
        "clinical_data": {
          "procedures": [
            {
              "name": "Stereotactic radiosurgery",
              "date": "2020-11",
              "location": "left and right lung",
              "modality": "other",
              "approach": "other"
            }
          ],
          "diagnoses": [
            {
              "code": "C34",
              "label": "Malignant neoplasm of bronchus and lung",
              "status": "active",
              "onset_date": "2020-11"
            }
          ],
          "imaging": [
            {
              "modality": "other",
              "body_part": "lung",
              "date": "2020-11",
              "type": "Radiotherapy"
            }
          ]
        }
      },
      "custom_id": "graph_072_N1"
    },
    {
      "id": "N3",
      "label": "Step 3",
      "customData": {
        "node_id": "C",
        "node_step_index": 2,
        "content": "September 2022: Started anlotinib 8mg orally once daily for 14 days every 3 weeks due to tumor progression.",
        "clinical_data": {
          "medications": [
            {
              "drug": "anlotinib",
              "dosage": "8mg",
              "frequency": "once daily",
              "modality": "oral",
              "start_date": "2022-09",
              "end_date": null,
              "indication": "tumor progression"
            }
          ]
        }
      },
      "custom_id": "graph_072_N2"
    },
    {
      "id": "N4",
      "label": "Step 4",
      "customData": {
        "node_id": "D",
        "node_step_index": 3,
        "content": "July 12th 2023: After 14 cycles of anlotinib treatment, patient presented with fasting plasma glucose of 26.1 mmol/L and urine ketone (+++). Admitted to Endocrinology Department of Chongqing General Hospital. Laboratory findings: GADA > 2000 IU/ml, ICA 43.4 COI, IAA < 1 CDI, Fasting blood glucose 24.3 mmol/L, Fasting insulin 0.83 uIU/L, Fasting C-peptide 0.13 ng/ml, Hemoglobin A1c 9.0 %, Hemoglobin 96 g/L, Serum albumin 27.2 g/L, TC 4.17 mmol/L, TG 0.67 mmol/L, LDL-C 2.43 mmol/L, Crea 87.7 umol/L, AST 16 U/L, ALT 11.6 U/L, TSH 5.32 mIU/L, FT3 4.41 pmol/L, FT4 18.0 pmol/L, pancreatic amylase 63.6 U/L, lipase 14.5 U/L. Diagnosed with type 1 diabetes and treated with insulin degludec in combination with insulin aspartate.",
        "clinical_data": {
          "labs": [
            {
              "test": "Fasting plasma glucose",
              "value": "26.1",
              "unit": "mmol/L",
              "timestamp": "2023-07-12"
            },
            {
              "test": "Urine ketone",
              "value": "+++",
              "unit": null,
              "timestamp": "2023-07-12"
            },
            {
              "test": "GADA",
              "value": "> 2000",
              "unit": "IU/ml",
              "timestamp": "2023-07-12"
            },
            {
              "test": "ICA",
              "value": "43.4",
              "unit": "COI",
              "timestamp": "2023-07-12"
            },
            {
              "test": "IAA",
              "value": "< 1",
              "unit": "CDI",
              "timestamp": "2023-07-12"
            },
            {
              "test": "Fasting blood glucose",
              "value": "24.3",
              "unit": "mmol/L",
              "timestamp": "2023-07-12"
            },
            {
              "test": "Fasting insulin",
              "value": "0.83",
              "unit": "uIU/L",
              "timestamp": "2023-07-12"
            },
            {
              "test": "Fasting C-peptide",
              "value": "0.13",
              "unit": "ng/ml",
              "timestamp": "2023-07-12"
            },
            {
              "test": "Hemoglobin A1c",
              "value": "9.0",
              "unit": "%",
              "timestamp": "2023-07-12"
            },
            {
              "test": "Hemoglobin",
              "value": "96",
              "unit": "g/L",
              "timestamp": "2023-07-12"
            },
            {
              "test": "Serum albumin",
              "value": "27.2",
              "unit": "g/L",
              "timestamp": "2023-07-12"
            },
            {
              "test": "TC",
              "value": "4.17",
              "unit": "mmol/L",
              "timestamp": "2023-07-12"
            },
            {
              "test": "TG",
              "value": "0.67",
              "unit": "mmol/L",
              "timestamp": "2023-07-12"
            },
            {
              "test": "LDL-C",
              "value": "2.43",
              "unit": "mmol/L",
              "timestamp": "2023-07-12"
            },
            {
              "test": "Crea",
              "value": "87.7",
              "unit": "umol/L",
              "timestamp": "2023-07-12"
            },
            {
              "test": "AST",
              "value": "16",
              "unit": "U/L",
              "timestamp": "2023-07-12"
            },
            {
              "test": "ALT",
              "value": "11.6",
              "unit": "U/L",
              "timestamp": "2023-07-12"
            },
            {
              "test": "TSH",
              "value": "5.32",
              "unit": "mIU/L",
              "timestamp": "2023-07-12"
            },
            {
              "test": "FT3",
              "value": "4.41",
              "unit": "pmol/L"
            }
          ]
        }
      },
      "custom_id": "graph_072_N3"
    },
    {
      "id": "N5",
      "label": "Step 5",
      "customData": {
        "node_id": "E",
        "node_step_index": 4,
        "content": "July 19th, 2023: Discharged with the hypoglycemic regimen (insulin degludec 5 units in the morning and insulin aspartate 4 units three times a day).",
        "clinical_data": {
          "medications": [
            {
              "drug": "C3258614",
              "dosage": "5 units",
              "frequency": "in the morning",
              "modality": "subcutaneous",
              "start_date": "2023-07-19",
              "end_date": null
            },
            {
              "drug": "C0729477",
              "dosage": "4 units",
              "frequency": "three times a day",
              "modality": "subcutaneous",
              "start_date": "2023-07-19",
              "end_date": null
            }
          ]
        }
      },
      "custom_id": "graph_072_N4"
    },
    {
      "id": "N6",
      "label": "Step 6",
      "customData": {
        "node_id": "F",
        "node_step_index": 5,
        "content": "One week after discharge: Reported a significant increase in blood glucose levels after re-starting anlotinib. Highest blood glucose level recorded was 30.1 mmol/L and insulin dose was increased to maintain his glucose levels.",
        "clinical_data": {
          "labs": [
            {
              "test": "Blood glucose",
              "value": "30.1",
              "unit": "mmol/L",
              "flag": "abnormal"
            }
          ],
          "medications": [
            {
              "drug": "anlotinib",
              "start_date": null,
              "end_date": null
            },
            {
              "drug": "insulin",
              "dosage": null,
              "frequency": null,
              "modality": null,
              "start_date": null,
              "end_date": null
            }
          ]
        }
      },
      "custom_id": "graph_072_N5"
    },
    {
      "id": "N7",
      "label": "Step 7",
      "customData": {
        "node_id": "G",
        "node_step_index": 6,
        "content": "Anlotinib treatment: Blood glucose decreased significantly, dosage of injected insulin was decreased.",
        "clinical_data": {
          "medications": [
            {
              "drug": "C4048413",
              "indication": "Neoplasm"
            }
          ],
          "labs": [
            {
              "test": "C0005767",
              "value": "decreased",
              "unit": null,
              "flag": "abnormal"
            }
          ]
        }
      },
      "custom_id": "graph_072_N6"
    },
    {
      "id": "N8",
      "label": "Step 8",
      "customData": {
        "node_id": "H",
        "node_step_index": 7,
        "content": "After two cycles of anlotinib treatment: Anlotinib was discontinued due to tumor progression and its significant negative impact on glucose metabolism.",
        "clinical_data": {
          "medications": [
            {
              "drug": "C1705538",
              "dosage": null,
              "frequency": null,
              "modality": null,
              "start_date": null,
              "end_date": null,
              "indication": null
            }
          ],
          "diagnoses": [
            {
              "code": null,
              "label": "tumor progression",
              "status": "active",
              "onset_date": null
            }
          ]
        }
      },
      "custom_id": "graph_072_N7"
    },
    {
      "id": "N9",
      "label": "Step 9",
      "customData": {
        "node_id": "I",
        "node_step_index": 8,
        "content": "After 16 cycles of anlotinib treatment: Laboratory parameters: GADA < 10 IU/ml, ICA < 1 COI, IAA < 1 CDI, Fasting blood glucose 8.7 mmol/L, Hemoglobin A1c 8.1 %, Hemoglobin 113 g/L, Serum albumin 30.4 g/L, TC 4.39 mmol/L, TG 0.58 mmol/L, LDL-C 2.15 mmol/L, Crea 90.1 umol/L, AST 17.8 U/L, ALT 12.3 U/L.",
        "clinical_data": {
          "labs": [
            {
              "test": "Fasting blood glucose",
              "value": "8.7",
              "unit": "mmol/L",
              "flag": "abnormal"
            },
            {
              "test": "Hemoglobin A1c",
              "value": "8.1",
              "unit": "%",
              "flag": "abnormal"
            },
            {
              "test": "Hemoglobin",
              "value": "113",
              "unit": "g/L",
              "flag": "abnormal"
            },
            {
              "test": "Serum albumin",
              "value": "30.4",
              "unit": "g/L",
              "flag": "abnormal"
            },
            {
              "test": "TC",
              "value": "4.39",
              "unit": "mmol/L",
              "flag": "normal"
            },
            {
              "test": "TG",
              "value": "0.58",
              "unit": "mmol/L",
              "flag": "normal"
            },
            {
              "test": "LDL-C",
              "value": "2.15",
              "unit": "mmol/L",
              "flag": "normal"
            },
            {
              "test": "Crea",
              "value": "90.1",
              "unit": "umol/L",
              "flag": "normal"
            },
            {
              "test": "AST",
              "value": "17.8",
              "unit": "U/L",
              "flag": "normal"
            },
            {
              "test": "ALT",
              "value": "12.3",
              "unit": "U/L",
              "flag": "normal"
            }
          ]
        }
      },
      "custom_id": "graph_072_N8"
    },
    {
      "id": "N10",
      "label": "Step 10",
      "customData": {
        "node_id": "J",
        "node_step_index": 9,
        "content": "Treatment",
        "clinical_data": {}
      },
      "custom_id": "graph_072_N9"
    }
  ],
  "edges": [
    {
      "from": "N1",
      "to": "N2",
      "data": {
        "edge_id": "A_to_B",
        "branch_flag": true,
        "content": "Patient received gyroknife radiotherapy for left and right lung malignancies 12 times."
      },
      "custom_id": "graph_072_N1_N2"
    },
    {
      "from": "N2",
      "to": "N3",
      "data": {
        "edge_id": "B_to_C",
        "branch_flag": true,
        "content": "Tumor progression led to the start of anlotinib 8mg orally once daily for 14 days every 3 weeks.",
        "transition_event": {
          "trigger_type": "progression",
          "trigger_entities": [],
          "change_type": "addition",
          "target_domain": "medication"
        }
      },
      "custom_id": "graph_072_N2_N3"
    },
    {
      "from": "N3",
      "to": "N4",
      "data": {
        "edge_id": "C_to_D",
        "branch_flag": true,
        "content": "After 14 cycles of anlotinib treatment, patient presented with hyperglycemia (fasting plasma glucose of 26.1 mmol/L) and urine ketone (+++), leading to a diagnosis of type 1 diabetes and treatment with insulin degludec in combination with insulin aspartate.",
        "transition_event": {
          "trigger_type": "symptom_onset",
          "trigger_entities": [],
          "change_type": "addition",
          "target_domain": "diagnosis"
        }
      },
      "custom_id": "graph_072_N3_N4"
    },
    {
      "from": "N4",
      "to": "N5",
      "data": {
        "edge_id": "D_to_E",
        "branch_flag": true,
        "content": "Patient was discharged with a hypoglycemic regimen of insulin degludec 5 units in the morning and insulin aspartate 4 units three times a day.",
        "transition_event": {
          "trigger_type": "medication_change",
          "trigger_entities": [],
          "change_type": "addition",
          "target_domain": "medication"
        }
      },
      "custom_id": "graph_072_N4_N5"
    },
    {
      "from": "N5",
      "to": "N6",
      "data": {
        "edge_id": "E_to_F",
        "branch_flag": true,
        "content": "One week after discharge, blood glucose levels significantly increased after re-starting anlotinib (highest recorded level was 30.1 mmol/L), and the insulin dose was increased.",
        "transition_event": {
          "trigger_type": "medication_change",
          "trigger_entities": [],
          "change_type": "escalation",
          "target_domain": "medication"
        }
      },
      "custom_id": "graph_072_N5_N6"
    },
    {
      "from": "N6",
      "to": "N7",
      "data": {
        "edge_id": "F_to_G",
        "branch_flag": true,
        "content": "During Anlotinib treatment, blood glucose decreased significantly, and the dosage of injected insulin was decreased.",
        "transition_event": {
          "trigger_type": "medication_change",
          "trigger_entities": [],
          "change_type": "deescalation",
          "target_domain": "medication"
        }
      },
      "custom_id": "graph_072_N6_N7"
    },
    {
      "from": "N7",
      "to": "N8",
      "data": {
        "edge_id": "G_to_H",
        "branch_flag": true,
        "content": "After two cycles of anlotinib treatment, anlotinib was discontinued due to tumor progression and its significant negative impact on glucose metabolism.",
        "transition_event": {
          "trigger_type": "medication_change",
          "trigger_entities": [],
          "change_type": "discontinuation",
          "target_domain": "medication"
        }
      },
      "custom_id": "graph_072_N7_N8"
    },
    {
      "from": "N8",
      "to": "N9",
      "data": {
        "edge_id": "H_to_I",
        "branch_flag": true,
        "content": "After 16 cycles of anlotinib treatment, laboratory parameters showed improvement in GADA, ICA, IAA, Fasting blood glucose, Hemoglobin A1c, Hemoglobin, and Serum albumin."
      },
      "custom_id": "graph_072_N8_N9"
    },
    {
      "from": "N9",
      "to": "N10",
      "data": {
        "edge_id": "I_to_J",
        "branch_flag": true,
        "content": "Treatment"
      },
      "custom_id": "graph_072_N9_N10"
    }
  ]
}